Biotechnology in Spain finds investors

Integral service around a transaction
BY : Diego GutiérrezSeptember Tue, 2014
bioOne of the main barriers to the growth of Spanish biotech companies is their small size (>95% less than 250 employees), which prevents them from accelerating their entry into foreign markets, for example. The main cause of this small size is due to the scarcity of funding or private investment. Although a specialised national biotech venture capital ecosystem is being generated and more and more deals are being closed with foreign investors, there is still much room for improvement.

The 50% rounds are oriented towards expansion processes.

Slide 2

Taking into account that out of the 10% of the rounds While the type of operation is not disclosed, it is significant that 50% of them have been dedicated to expansion and growth plans. The next group is occupied by companies in their early stages (seed, startup or spinoff) accounting for 20% of the transactions. This reflects the fact that the sector is not a mature sector, with expectations of growth in the next few years. investors and that consolidation operations are rare.

The buildup operation, within the metabolomics activities carried out by the Basque company in 2010, stands out. OWl genomics that bought the Gipuzkoan company MD Renal. Since then, OWl, a company in which MD Renal has a majority holding CRBtook over the management of the new subsidiary.

Catalonia and Madrid account for 50% of the companies financed.

Slide 3

Of all the companies analysed in the biotechnology sector that have received rounds in recent years (a total of 107 companies), almost half of them are based in Catalonia (31 companies) and Madrid (20 companies). The next C.C.A.A. leading the ranking are the Basque Country, Andalusia and Navarre. Catalonia's leadership may be due to the traction provided by the ecosystem of pharmaceutical companies located in Barcelona.

The appearance of Navarre in the top 5 is a reflection of the influence that has been exerted by the University of Navarra and its bio-health research centres in the development of new companies in the sector.

Other related links:

List of biotech investors Spain

List of investors in biomarker biotechnology

We are currently preparing a report on the current state of crowdfunding as an alternative means of financing. If you are interested in receiving this report, please leave us your email address.


The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?